SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): March 31, 2004
MIRAVANT MEDICAL TECHNOLOGIES
(Exact name of Registrant as specified in its charter)
Delaware 0-2554 77-0222872
(State or other jurisdiction of (Commission File Number) I.R.S. Employer
incorporation or organization) Identification Number)
336 Bollay Drive
Santa Barbara, CA 93117
(Address of principal executive offices)
(805) 685-9880
(Registrant's telephone number, including area code)
ITEM 5. Other Events and Regulation FD Disclosure
On March 31, 2004 Miravant Medical Technologies ("Miravant") announced that it
submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration
(FDA) seeking marketing approval of SnET2-PDT as a new treatment for patients
with wet age-related macular degeneration (AMD). SnET2-PDT has been designated a
Fast Track product by the FDA, and Miravant has requested priority review status
for the drug. Within 60 days of NDA submission, the FDA will make a
determination to accept or refuse to file the NDA and, if accepted, will
designate its review status.
A copy of the press release issued on March 31, 2004 by Miravant announcing the
NDA submission is attached hereto as Exhibit 99.1 and is incorporated by
reference in its entirety.
ITEM 7. Financial Statements and Exhibits
Exhibit Number Exhibit
99.1 Press release issued on March 31, 2004
announcing the NDA submission
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act or 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Miravant Medical Technologies
(Registrant)
Date: April 1, 2004
By: /s/ John M. Philpott
-------------------------
Name: John M. Philpott
Title: Chief Financial Officer
Exhibit Index
Exhibit Number Exhibit
99.1 Press release issued on March 31, 2004
announcing the NDA submission